Global High-Priority Regulatory Events — March 17, 2026

17-03-2026

Carlisle Companies Incorporated's DEF 14A proxy statement, filed March 17, 2026, provides pay versus performance disclosures via XBRL tags for fiscal years 2021-2025, covering the Principal Executive Officer (PEO) and Non-PEO Named Executive Officers (NEOs), including adjustments for equity awards, pension values, and fair value changes. The filing details the non-employee director compensation program, comprising annual retainers (partly in shares), committee leadership fees, restricted share grants, and a deferred compensation plan, with benchmarking conducted in April 2024 by Willis Towers Watson confirming market competitiveness. It also outlines board communication protocols addressed to Mr. Frias (Lead Independent Director) and a strict director retirement policy requiring resignation at age 72 or after 18 years of service.

• ·Employee directors receive no additional compensation for board service.
• ·Corporate Governance and Nominating Committee reviews director pay at least every two years.
• ·Communications to directors screened to exclude commercial, irrelevant, or improper topics.
• ·Board address: 16430 North Scottsdale Road, Suite 400, Scottsdale, Arizona 85254, Attention: Secretary.

17-03-2026

Vesicor Therapeutics, Inc., an early-stage biotech and proposed de-SPAC acquisition target for Black Hawk Acquisition Corp (Nasdaq: BKHA, BKHAU, BKHAR), appointed Michael Tolentino, M.D., as CEO effective March 17, 2026, succeeding founder Luo Feng, Ph.D., who transitions to Chief Scientific Officer. Tolentino brings over 20 years of biotech experience, including inventing contributions to Avastin, founding Acuity Pharmaceuticals (merged into OPKO Health), scientific founding Promedior (sold to Roche), and co-founding Aviceda Therapeutics (raised $207.5M Series C) and Avdarna Therapeutics. The company plans to accelerate IND-enabling studies toward a 2027 FDA IND submission, though it notes standard forward-looking risks including lack of current FDA approval and funding needs.

• ·Vesicor has not commenced FDA regulatory approval process for its sole product candidate as of March 17, 2026
• ·Tolentino co-founded Aviceda Therapeutics and served as CSO (2018-2021), CTO/CIO (2018-2025), and board member (2018-2024)
• ·Aikium's Yotta-ML platform targets GLP-1, GIP-1, glucagon agonists, checkpoint inhibitors, and cancer antigens for microvesicle conjugation

17-03-2026

Vedanta Limited, promoter of Hindustan Zinc Limited holding 60.71% (2,565,271,353 shares), created a new encumbrance on 2,116,884,819 shares (50.10% of total share capital) via a Debenture Trust Deed dated March 12, 2026, in favor of Axis Trustee Services Limited as trustee for ₹2,575 Cr debenture holders. This increases total encumbered promoter shares to 2,359,003,222 (55.83% of total capital), equivalent to 91.96% of promoter holding, amid multiple existing encumbrances. The covenant mandates Vedanta to retain legal and beneficial ownership of at least 50.1% of HZL shares until full debenture redemption.

• ·Existing encumbrances include 10 events from March 2022 to March 2026, with prior pledges/non-disposal undertakings totaling high portions (e.g., 5.77% or 243,609,285 shares under Encumbrance 1)
• ·Disclosure filed March 16, 2026, under SEBI Takeover Regulations 31 and Master Circular Feb 16, 2023
• ·Vedanta restricted from disposing or creating security over 50.1% of HZL shares until debenture redemption

17-03-2026

Videocon Industries Limited, under consolidated Corporate Insolvency Resolution Process (CIRP) since NCLT order dated June 6, 2018 (read with orders dated August 8, 2019 and September 25, 2019), has provided pre-facto intimation of its 59th Committee of Creditors (CoC) meeting for itself and 12 other Videocon group companies, scheduled for March 18, 2026. The notice complies with SEBI LODR Regulations and IBBI Regulations. No financial outcomes or resolutions from prior meetings are disclosed in this procedural update.

• ·Scrip Code: 511389; Symbol: VIDEOIND
• ·Insolvency Professional Regn. No.: IBBI/IPA-003/IP-N000103/2017-2018/11158
• ·CIN: L99999MH1986PLC103624

17-03-2026

Sumeet Industries Limited has been declared the successful bidder (H1) for the acquisition of Nakoda Limited's Phase-3 Chips Manufacturing Plant under slump sale via the Corporate Insolvency Resolution Process (CIRP) under IBC, 2016, at a total consideration of ₹23.47 Cr. This acquisition includes land (11,534 sq. meters) and plant & machinery at Village Karanj, Surat, Gujarat, expanding the company's Polyester Chips production capacity by approximately 400 Tons per day. The Board also approved the Draft Letter of Offer for a proposed Rights Issue of Equity Shares.

• ·E-Auction conducted on 09 March 2026 via EBKRAY/BAANKNET platform.
• ·Letter of Intent dated 11.03.2026; acquisition to complete within 180 days from 17.03.2026 subject to approvals.
• ·Nakoda Limited incorporation date: 13.08.1984; under CIRP with Liquidator appointed by NCLT Ahmedabad on 08 February 2023.
• ·Assets located at Village Karanj, Tal Mandvi, District Surat, Gujarat-394110.
• ·Board meeting held on 17.03.2026 from 11:00 A.M. to 12:35 P.M.

17-03-2026

Patel Integrated Logistics Limited has initiated the process of voluntary delisting of its equity shares from the Calcutta Stock Exchange Limited (CSE), as approved by the Board of Directors on March 16, 2026, with newspaper publications in The Free Press Journal, Pratahkal, and Aajkaal Kolkata on March 17, 2026. The delisting from CSE will not prejudice shareholder interests, as shares continue to remain listed and traded on BSE Limited. No financial impacts or changes in trading status on major exchanges are mentioned.

• ·Scrip code: 526381 (BSE), NSE Symbol: PATINTLOG
• ·Newspaper publications dated March 17, 2026
• ·Company website: www.patel-india.com

17-03-2026

The Hon’ble NCLT Allahabad Bench orally pronounced an order on March 17, 2026, approving the resolution plan dated October 14, 2025 (with clarifications dated November 5, 2025) submitted by Adani Enterprises Limited for Jaiprakash Associates Limited under Section 31 of the IBC. The plan mandates delisting of all existing securities, NIL consideration to shareholders, and complete cancellation of pre-CIRP share capital (including equity, preference shares, and convertible instruments) for zero value on the Effective Date (within 90 days of NCLT approval). A detailed disclosure will follow upon receipt of the written order.

• ·Prior disclosure dated November 27, 2025 regarding application for resolution plan approval.
• ·Scrip Codes: 532532 (BSE), JPASSOCIAT (NSE).
• ·Liquidation value insufficient to satisfy secured creditors in full, per Successful Resolution Applicant.

17-03-2026

A Paradise Acquisition Corp., a SPAC, is merging with Enhanced, an innovative sports company launching the Enhanced Games that permit FDA-approved performance-enhancing substances under medical supervision to prioritize athlete health, safety, and higher compensation compared to traditional athletics. CEO Max Martin discusses overcoming PED stigma, the Enhanced Games Medical Program run as a clinical study in Abu Dhabi with SSMC Hospital, and benefits for both elite and returning athletes. Accelerate Arbitrage Fund discloses a long position in A Paradise Acquisition shares and rights.

• ·Enhanced Games idea originated roughly 2.5 years ago.
• ·Athletes receive comprehensive baseline assessments and continuous medical screenings as part of the Medical Program.
• ·Focus on two athlete types: prime athletes aiming to break records and older athletes (e.g., mid-30s) seeking personal bests.

17-03-2026

Eureka Acquisition Corp issued an interest-free promissory note for $150,000 to Marine Thinking Inc. on March 13, 2026, as disclosed in an 8-K filing on March 17, 2026. The note matures upon consummation of a Business Combination or the Company's term expiry and may be converted by the Payee into private units at $10 per unit. No period-over-period financial metrics are provided in the filing.

• ·Note governed by New York law
• ·Conversion notice required at least two business days prior to Business Combination closing
• ·No personal liability for officers, directors, employees, or stockholders
• ·Prospectus File No. 333-277780 referenced

17-03-2026

Mechanics Bancorp reported net income of $266M in 2025, up 817% YoY from $29M, boosted by a $145M bargain purchase gain from the September 2, 2025 merger with HomeStreet Bank and noninterest income swing to $223M from a $139M loss. Net interest income grew 13% YoY to $586M with NIM expanding 12 bps to 3.43%, while total assets expanded 36% to $22.4B and deposits rose 36% to $19.0B. However, provision for credit losses on loans increased to $20.5M from a $1.6M reversal, nonaccrual loans tripled to $43M (0.30% of total loans), and noninterest expenses rose 36% to $470M driven by $73M acquisition/integration costs.

• ·Common equity Tier 1 capital ratio for Mechanics Bancorp: 14.09% (newly reported post-merger)
• ·Tangible common equity ratio declined to 8.48% from 9.10%
• ·Loans to deposits ratio increased to 74.52% from 69.17%
• ·Full time equivalent employees grew 34% to 1,921

17-03-2026

For the six months ended January 31, 2026, PURE BIOSCIENCE, INC. reported revenue growth of 21.7% YoY to $1.152M, driven by strong performance in PURE Hard Surface (+46.8% to $1.136M for the month), while SILVÉRION revenue declined sharply 91.9% to $14,000. Net loss narrowed 16.0% YoY to $1.249M amid lower G&A expenses, however interest expense rose to $195,000 from $132,000 and dilutive securities outstanding surged 63.3% to 68.6M shares. Convertible notes increased to $5.52M principal plus $625,000 accrued interest.

• ·Fiscal 2026 Notes issued totaling $720K at 6.34%-6.68% interest, maturing Oct-Dec 2028.
• ·G&A expenses decreased 10.2% YoY to $1.498M for six months.
• ·Interest expense increased 47.7% YoY to $195K for six months.

17-03-2026

Pelican Acquisition Corp disclosed under Item 7.01 three promotional discussions on March 13, 14, and 16, 2026, featuring Greenland Energy Company's CEO Robert Price and incoming director Larry G. Swets, Jr., regarding the pending Business Combination with Greenland Exploration Limited, March GL, and PubCo. The filing furnishes transcripts as Exhibits 99.1 and 99.2 and references a Registration Statement on Form S-4 declared effective on February 17, 2026. It emphasizes forward-looking statements with extensive risk factors, including potential delays, redemptions, and failure to complete the merger.

• ·Registration Statement on Form S-4 effective February 17, 2026.
• ·Pelican 10-Q filings: July 31, 2025 (filed September 15, 2025), April 30, 2025 (filed June 27, 2025).
• ·S-1 effective May 22, 2025.

17-03-2026

American Rebel Holdings Inc entered into a Securities Purchase Agreement issuing a promissory note to 1800 Diagonal Lending LLC with a principal amount of $124,200 purchased for $108,000 (including $16,200 OID), requiring total repayments of $147,487 over 15 monthly installments from April 15, 2026 to June 15, 2027 at an effective 15% interest rate. The note includes high default interest of 22%, acceleration to 150% of outstanding amounts upon events of default, and conversion rights into common stock (limited to 4.99% beneficial ownership, subject to Nasdaq 19.99% rule without stockholder approval), posing dilution risk. Prepayment is permitted at 95% of principal plus interest within the first 180 days without penalty.

• ·5-day grace period for payments; missed payment triggers Event of Default.
• ·Covenant restricts sale of significant assets without Holder consent to avoid shell company status.
• ·Events of Default include failure to pay (after 5 business days notice), covenant breaches (after 20 days notice), bankruptcy, delisting from Exchanges, non-compliance with Exchange Act reporting.
• ·Conversion rights exercisable only after Event of Default; Notice of Conversion must be before 6pm NY time.
• ·Prepayment requires 3 Trading Days prior notice; no partial prepayments except as specified.

17-03-2026

Brookfield Infrastructure Corp's annual report for year ended December 31, 2025, reports cash from operating activities declining 8% YoY to $1,608M from $1,743M, while cash used in investing activities improved significantly with a reduced outflow of $612M from $1,110M. Cash used in financing activities worsened to $1,291M outflow from $428M. Non-recourse borrowings totaled $13.5B with projected interest expense of $4.95B, and base management fees grew 6% YoY to $71M.

• ·Exchangeable shares increased slightly to 132,994,956 as of Dec 31, 2025 from 132,051,909 in 2024 (+0.7%).
• ·USD stock highs in Q4 2025 reached $36.41, comparable to $36.42 in Q4 2024, with trading volume increasing to 36.2M units from 21.9M.

17-03-2026

Brookfield Infrastructure Partners L.P. reported strong FY2025 financials with revenues up 9.8% YoY to $23.1B, FFO up 6.4% to $2.6B, and net income attributable to the partnership surging 179% to $1.1B, driven by higher other income. However, mark-to-market losses widened to $548M from $26M, and in the Utilities segment, while total Adjusted EBITDA grew 6.1% to $1.3B, Regulated Transmission EBITDA was essentially flat at $552M (up 0.9%) after declining from $631M in 2023. The year featured active portfolio management with acquisitions totaling over $2B (e.g., HomeServe for $1.2B) and divestitures generating ~$1.5B in net proceeds.

• ·Total assets grew 22.5% to $128.2B as of Dec 31, 2025.
• ·Non-recourse borrowings increased to $59.6B from $46.6B.
• ·FFO payout ratio stable at 66% in 2025 vs 67% in 2024.
• ·Agreed sale of Mantiqueira expected to close H1 2026 for $150M.

17-03-2026

Cortigent, Inc. (CRGT), a spin-off from Vivani Medical, Inc., is filing Amendment No. 17 to its S-1 for a firm commitment IPO of 1,500,000 shares of common stock at an anticipated $10.00 per share, with an underwriter option for 225,000 additional shares; post-IPO, Vivani will own approximately 77% of voting power, making Cortigent a controlled company. The company develops investigational brain implant devices including the Orion Visual Prosthesis (targeting $4B US TAM for 82,000 profoundly blind Americans) and Stroke Recovery System ($6B annual US TAM amid 610,000 annual strokes), building on the discontinued Argus II system. As an emerging growth company with no established public market and high investment risks, including FDA approval uncertainties for its products, the offering highlights promising markets but pre-commercial status.

• ·Argus II sales discontinued in 2019 to refocus on Orion
• ·Orion completed 6-year Early Feasibility Study in March 2025 with FDA Breakthrough Device designation
• ·Applied for NYSE American listing under symbol CRGT; offering will not proceed without approval
• ·Emerging growth company and smaller reporting company status
• ·Investigational devices (Orion and Stroke Recovery) require FDA approval; no assurance of success

17-03-2026

Two Harbors Investment Corp. adjourned its Special Meeting of Stockholders to March 24, 2026, at 11:00 a.m. ET to solicit additional proxies in favor of its proposed acquisition by UWM Holdings Corporation. The Board unanimously recommends voting 'FOR' the Merger Proposal, Non-Binding Compensation Advisory Proposal, and Adjournment Proposal, as detailed in the proxy statement dated February 9, 2026. While the Board views the transaction as in stockholders' best interest, the communication emphasizes significant risks and uncertainties, including potential failure to obtain approvals, integration challenges, and adverse market effects.

• ·Proxy statement/prospectus declared effective by SEC on February 9, 2026; mailing commenced on or about February 12, 2026.
• ·Assistance for voting available via D.F. King toll-free at (888) 887-0082.
• ·Two Harbors 10-K for FY ended December 31, 2025 filed February 17, 2026; UWM 10-K filed February 25, 2026.

17-03-2026

Tenon Medical, Inc. closed a private placement of senior convertible promissory notes with institutional and high net worth investors for gross proceeds of $4.3 million before placement agent fees. The notes have a 20% original issue discount, aggregate principal of $4.3 million, mature on September 11, 2026, and are convertible into common stock after a six-month anniversary at 80% of the VWAP for the prior three trading days. Net proceeds will support commercial expansion, product development, clinical studies, working capital, and general corporate purposes.

• ·Notes not registered under Securities Act of 1933; may not be offered or sold absent registration or exemption
• ·WallachBeth Capital, Inc. acted as placement agent
• ·National launch of Catamaran SI Joint Fusion System in October 2022
• ·Company formed in 2012

17-03-2026

On March 15, 2026, Sean Smith resigned as Chief Accounting Officer of QXO, Inc., effective immediately, to pursue employment closer to his family, and agreed to serve in an advisory role until June 30, 2026, with continued compensation including prorated salary, bonus, and equity vesting. The departure is not due to any disagreements on accounting principles, financial statements, or internal controls. On March 16, 2026, Robert Loughran was appointed as Interim Chief Accounting Officer, effective immediately, while the company searches for a permanent successor.

• ·No family relationships between Mr. Loughran and any directors or executive officers.
• ·No arrangements or understandings pursuant to which Mr. Loughran was selected as an officer.
• ·No material transactions involving Mr. Loughran subject to Item 404(a) of Regulation S-K.
• ·Mr. Loughran's prior roles: Partner at Elm Street Advisors (since 2023), CFO at Greenidge Generation Holdings (Jan 2022-Oct 2023), CAO at Greenidge (Jun 2021-Jan 2022), VP Corporate Controller at Tronox Holdings PLC (Apr 2018-Jun 2020), various senior roles at Avon including Group VP CAO (Mar 2016-Mar 2019) and VP Corporate Controller (May 2012-Mar 2016).
• ·Mr. Loughran is a Certified Public Accountant with a BS from University of Connecticut.

17-03-2026

McEwen Inc. reported full-year 2025 revenue of $197.6 million, up 13% YoY from $174.5 million in 2024, driven by a 48% higher average realized price of $3,532 per GEO despite a 22% decline in GEO sales from 100% owned operations to 58,552. Consolidated GEO sales fell 16% to 113,732, including an 9% drop in attributable GEOs from the San José mine to 55,180. Additionally, on February 6, 2026, McEwen Copper secured a loan facility of up to $240 million, with $28.5 million drawn to date at 12% annual interest, to fund the Los Azules Project and other purposes.

• ·Loan proceeds for McEwen Copper to be used for general corporate purposes, working capital, going public transaction costs, and advancing Los Azules Project toward Final Investment Decision.
• ·Company received 203,280 transferable warrants to purchase McEwen Copper shares at $40 per share as part of loan agreement.
• ·Argentina corporate income tax rate changed to progressive 25%-35% for fiscal years starting on/after Jan 1, 2021, with annual inflation adjustments from Jan 2022.

17-03-2026

Ethos Technologies Inc. reported revenue of $387.6M for FY 2025, up 52% YoY from $254.9M, driven by strong growth in DTC channel revenue (+40% to $242.5M) and third-party channel revenue (+79% to $145.1M). Gross profit rose 53% to $380.9M with margin expansion to 98% from 97%, and Adjusted EBITDA increased 55% to $89.0M with flat 23% margin; however, net income margin slightly declined to 18% from 19%, sales and marketing expenses surged 54% to $229.3M (59% of revenue), and G&A expenses jumped 77% to $39.6M (10% of revenue).

• ·Contribution profit FY 2025: $162.0M (42% margin) vs FY 2024: $104.6M (41% margin)
• ·Cost of revenue FY 2025: $6.7M vs FY 2024: $6.5M
• ·Depreciation and amortization FY 2025: $5.4M (flat YoY)
• ·Income tax expense FY 2025: $4.6M vs FY 2024: $5.1M

17-03-2026

Hammer Technology Holdings Corp. reported a reduced net loss from continuing operations of $153K for the three months ended January 31, 2026, compared to a $280K loss in the prior year period, driven by lower operating expenses ($139K vs. $348K). Cash and equivalents increased to $28K from $18K at July 31, 2025, supported by $339K in related-party financing, however total assets declined 22% to $182K amid amortization of intangibles, while total liabilities rose 19% to $1.15M and stockholders' deficit worsened to $(968K). For the six months, operating cash burn improved to $328K from $497K, but the company continues to generate no revenue from continuing operations.

• ·Intangible assets declined to $154K from $216K due to amortization.
• ·Selling, general and administrative expenses for six months ended Jan 31, 2026: $242K (down 33% YoY from $363K).
• ·No revenue reported from continuing operations in any period.
• ·Gain on disposal of subsidiaries in prior year discontinued operations: $1.66M for three and six months ended Jan 31, 2025.

17-03-2026

Xerox Holdings Corp reported total revenue of $7.0B for the year ended December 31, 2025, up 12.9% YoY from $6.2B in 2024, driven by IT Solutions revenue surging 112.6% to $761M and post-sale revenue growing 14.3% to $5.5B. However, Print and Other segment profit declined 29.5% to $279M from $396M, total segment profit fell 18.9% to $321M, adjusted operating profit dropped 17.9% to $248M, and total gross margin compressed 4.4 percentage points to 27.1%. Pre-tax loss narrowed to $488M from $1.2B but remained negative amid higher expenses.

• ·Equipment gross margin declined to 21.4% in 2025 from 30.2% in 2024 (-8.8 pts)
• ·Post sale gross margin declined to 28.6% in 2025 from 31.9% in 2024 (-3.3 pts)
• ·SAG as % of revenue improved slightly to 23.6% in 2025 from 24.7% in 2024 (+1.1 pts)
• ·Non-financing interest expense rose to $248M in 2025 from $119M in 2024
• ·Other expenses, net increased to $360M in 2025 from $158M in 2024

17-03-2026

BW Industrial Holdings Inc., a Delaware-based general building contractor for nonresidential buildings, filed Amendment No. 2 to its S-1 registration statement on March 17, 2026, for an IPO of 2,625,000 shares of common stock on NYSE American under symbol BWGC, with an anticipated price range of $6-$7 per share (midpoint $6.50), targeting gross proceeds of $17.1M. Net proceeds to the company before expenses are estimated at $16.0M after 6% underwriting discounts of $1.0M to lead underwriter Eddid Securities USA Inc., with a 45-day over-allotment option for up to 393,750 additional shares potentially increasing totals to $19.6M gross and $18.4M net. Post-IPO, CEO and Director Yunlong Zhang will retain control with approximately 57.21% voting power, qualifying the company as a 'controlled company' and emerging growth company.

• ·Company address: 2825 Wilcrest Drive, Suite 421, Houston, TX 77042.
• ·I.R.S. Employer Identification No.: 33-4856491.
• ·Standard Industrial Classification Code: 1541 (General Building Contractors - Nonresidential Buildings).
• ·SEC File Number: 333-292504.
• ·Emerging growth company electing reduced reporting requirements under JOBS Act.

17-03-2026

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing CNS cancer therapies, appointed David Choi as Chief Accounting Officer effective March 13, 2026, to oversee accounting, financial reporting, internal controls, and governance as it advances Phase II trials. Mr. Choi brings over a decade of experience from Blythe Global Advisors, Grant Thornton, and Ernst & Young, including SEC reporting and SOX compliance. The appointment supports the company's growth with its NEO™ platform, including NEO100™ and NEO212™ under FDA Fast-Track status.

• ·Patent protections extending to 2038.
• ·Exclusively licensed worldwide patent portfolio from University of Southern California for NEO100, NEO212, and related products.
• ·Risk factors referenced in 10-Q for three months ended March 31, 2025.

17-03-2026

M3-Brigade Acquisition VI Corp., a SPAC formed on June 5, 2025, reported net income of $4.15M for the period ended December 31, 2025, driven by $4.61M in interest income on Investments held in Trust Account totaling $349.6M. However, the company recorded an operating loss of $0.43M from general and administrative costs and a shareholders' deficit of $15.56M primarily due to accretion of Class A ordinary shares subject to redemption. Total assets were $350.8M, including $0.88M in cash, with $34.5M Class A shares at $10.13 redemption value and deferred underwriting fees of $16.4M.

• ·Inception date: June 5, 2025
• ·Balance sheet date: December 31, 2025
• ·Filing date: March 17, 2026
• ·Class A redemption value: $10.13 per share
• ·Net income per share: $0.14 (basic and diluted for both Class A and B)
• ·Auditor: Independent Registered Public Accounting Firm (PCAOB ID: 100)